BioNTech SE
NASDAQ:BNTXBiotechnology
-$1.41 today
- Market cap
- $20.64B
- Beta
- 1.32
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$4.93
Volume 1.24M
Average 1.11M
BNTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
BioNTech SENASDAQ: BNTX
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation outflow grows to €0
Q2 FY2026 stock-based compensation was €0, compared with €0 a year earlier. Trailing-twelve-month stock-based compensation was €0.
Context
- Stock-based compensation amounted to 0.0% of revenue in FY2025, down 3.7 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near €0 or moves back toward the trailing-twelve-month quarterly average of €0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
EUR · from the cash flow
- Latest · FY2025
- 0 EUR
- Year-over-year change
- -100.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 100.9M | +96.3% |
| FY2023 | 2023-12-31 | 51.4M | -52.7% |
| FY2022 | 2022-12-31 | 108.6M | +15.7% |
| FY2021 | 2021-12-31 | 93.9M | — |
Stock-Based Compensation vs competitors
How BNTX compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Stock-based compensation amounts to 0.0% of revenue for BNTX, versus a peer median of 8.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $187.88M USD | -31.7% | +9.8% | 3.2% | |
| LTM Sep 2026 | $88.18M USD | +44.6% | +49.9% | 9.8% | |
| LTM Jun 2026 | $71M USD | — | — | 1.7% | |
| LTM Sep 2026 | $46.65M USD | -42.2% | -9.8% | 12.3% | |
| LTM Jun 2026 | $39.03M USD | +10.2% | -4.0% | 37.2% | |
| LTM Sep 2026 | $34.15M USD | -8.0% | -2.9% | 18.7% | |
| LTM Mar 2026 | $28.21M USD | +14.1% | — | 7.3% | |
| LTM Mar 2026 | $12.55M USD | -55.6% | -11.3% | 8.0% | |
| LTM Mar 2026 | €7.38M EUR | -44.8% | — | 19.8% | |
| LTM Jun 2026 | €0 EUR | — | — | 0.0% | |
| LTM Dec 2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding BNTX) | — | -19.8% | -3.5% | 8.9% | |
Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 15.05B | 12.95B | 1.19B | (677.7M) | (1.09B) |
| Depreciation & Amortization | 75.2M | 123.3M | 183.4M | 298M | 367.69M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 70.98M |
| Stock-Based Compensation | 93.9M | 108.6M | 51.4M | 100.9M | 0 |
| Change in Working Capital | (10.73B) | 4.52B | 5.57B | 1.22B | 516.57M |
| Accounts Receivables | (11.81B) | 4.37B | 5.37B | 387.7M | 1.04B |
| Inventory | (438.4M) | 62.9M | 81.9M | 74.5M | 170.88M |
| Accounts Payables | 1.52B | 85.7M | 118.9M | 758.4M | (695.23M) |
| Other Working Capital | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | (3.6B) | (4.13B) | (1.62B) | (734.1M) | 574.01M |
| Operating Cash Flow | 889.7M | 13.58B | 5.37B | 207.7M | 438M |
| Capital Expenditures | (154M) | (363.3M) | (705.5M) | (452.3M) | (168.19M) |
| Acquisitions (Net) | (20.8M) | 0 | (336.9M) | 0 | 183.27M |
| Purchases of Investments | (394.7M) | (47.8M) | (6.98B) | (12.37B) | (10.97B) |
| Sales of Investments | 0 | 375.2M | 1.19B | 10.74B | 9.14B |
| Other Investing Activities | (23.1M) | (33.5M) | (576.59M) | (164.6M) | 0 |
| Investing Cash Flow | (566.1M) | (35.3M) | (6.95B) | (2.08B) | (2.37B) |
| Debt Repayment | (66.7M) | (59.1M) | (40.1M) | (45.9M) | (10.85M) |
| Common Stock Issued | 160.9M | 110.5M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (986.4M) | (738.5M) | 0 | 0 |
| Dividends Paid | 0 | (484.3M) | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | (39.96M) |
| Financing Cash Flow | 94.2M | (1.42B) | (778.6M) | (45.9M) | (50.81M) |
| Effect of Forex Changes | 64.7M | 60.1M | 150.3M | 14.8M | 1.05B |
| Net Change in Cash | 482.5M | 12.18B | (2.21B) | (1.9B) | (931.17M) |
| Free Cash Flow | 735.7M | 13.21B | 4.67B | (244.6M) | 269.81M |
BioNTech SE
NASDAQ:BNTX
Intrinsic Alpha fair value
Locked
Current Price
$83.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.